Morgan Stanley analyst Kallum Titchmarsh downgraded 10x Genomics (TXG) to Equal Weight from Overweight with a price target of $20, up from $17, as the analyst assumed coverage of the stock. The recent stock rally places the multiple in a “reasonable spot” relative to growth and peers, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics downgraded to Equal Weight from Overweight at Morgan Stanley
- 10x Genomics Announces Chief Legal Officer Retirement
- 10x Genomics price target raised to $19 from $15 at Piper Sandler
- 10X Genomics Earnings Call: Mixed Results Amid Challenges
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks